Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 5
2019 6
2020 6
2021 2
2022 2
2023 5
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL.
Miyazaki K, Sakai R, Iwaki N, Yamamoto G, Murayama K, Nishikori M, Sunami K, Yoshida I, Yano H, Takahashi N, Okamoto A, Munemoto S, Sawazaki A, Suehiro Y, Fukuhara N, Wake A, Arai A, Masaki Y, Toyama K, Yokoyama A, Tsunemine H, Hasegawa Y, Matsumoto K, Yamada T, Nishimura Y, Tamaru S, Asano N, Miyawaki K, Izutsu K, Kinoshita T, Suzuki R, Ohshima K, Kato K, Katayama N, Yamaguchi M. Miyazaki K, et al. Cancer Sci. 2023 Jun;114(6):2689-2691. doi: 10.1111/cas.15784. Epub 2023 Mar 16. Cancer Sci. 2023. PMID: 36929591 Free PMC article. Clinical Trial. No abstract available.
Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406.
Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Kameoka Y, Takayama N, Hanamura I, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K, Nagai H. Ogura M, et al. Cancer Sci. 2023 Aug;114(8):3461-3465. doi: 10.1111/cas.15849. Epub 2023 May 26. Cancer Sci. 2023. PMID: 37232264 Free PMC article.
Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study).
Tokunaga M, Machida N, Mizusawa J, Ito S, Yabusaki H, Hirao M, Watanabe M, Imamura H, Kinoshita T, Yasuda T, Hihara J, Fukuda H, Yoshikawa T, Boku N, Terashima M. Tokunaga M, et al. Gastric Cancer. 2024 May;27(3):580-589. doi: 10.1007/s10120-024-01467-9. Epub 2024 Jan 19. Gastric Cancer. 2024. PMID: 38243037 Clinical Trial.
Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501).
Terashima M, Iwasaki Y, Mizusawa J, Katayama H, Nakamura K, Katai H, Yoshikawa T, Ito Y, Kaji M, Kimura Y, Hirao M, Yamada M, Kurita A, Takagi M, Boku N, Sano T, Sasako M; Stomach Cancer Study Group, Japan Clinical Oncology Group. Terashima M, et al. Gastric Cancer. 2019 Sep;22(5):1044-1052. doi: 10.1007/s10120-019-00941-z. Epub 2019 Mar 2. Gastric Cancer. 2019. PMID: 30827001 Clinical Trial.
Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy - a supplementary analysis of JCOG0601.
Shimada K, Ohmachi K, Machida R, Ota S, Itamura H, Tsujimura H, Takayama N, Shimada T, Kurosawa M, Tabayashi T, Shimoyama T, Ohshima K, Miyazaki K, Maruyama D, Kinoshita T, Ando K, Hotta T, Tsukasaki K, Nagai H. Shimada K, et al. Ann Hematol. 2024 Jun;103(6):2021-2031. doi: 10.1007/s00277-024-05620-3. Epub 2024 Jan 27. Ann Hematol. 2024. PMID: 38280061 Free PMC article. Clinical Trial.
Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators.
Inoue K, Ninomiya J, Saito T, Kimizuka K, Kurosumi M. Inoue K, et al. BMC Cancer. 2018 Jun 20;18(1):671. doi: 10.1186/s12885-018-4556-6. BMC Cancer. 2018. PMID: 29925345 Free PMC article. Clinical Trial.
Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
Niikura N, Shimomura A, Fukatsu Y, Sawaki M, Ogiya R, Yasojima H, Fujisawa T, Yamamoto M, Tsuneizumi M, Kitani A, Watanabe J, Matsui A, Takahashi Y, Takashima S, Shien T, Tamura K, Saji S, Masuda N, Tokuda Y, Iwata H. Niikura N, et al. Breast Cancer Res Treat. 2018 Jan;167(1):81-87. doi: 10.1007/s10549-017-4489-9. Epub 2017 Sep 11. Breast Cancer Res Treat. 2018. PMID: 28895005 Clinical Trial.
25 results